AR038178A1 - COMBINATION OF PTM INHIBITORS OR INHIBITORS OF THE APOB SECRETION WITH FIBRATES FOR USE AS MEDICATIONS - Google Patents

COMBINATION OF PTM INHIBITORS OR INHIBITORS OF THE APOB SECRETION WITH FIBRATES FOR USE AS MEDICATIONS

Info

Publication number
AR038178A1
AR038178A1 ARP030100056A ARP030100056A AR038178A1 AR 038178 A1 AR038178 A1 AR 038178A1 AR P030100056 A ARP030100056 A AR P030100056A AR P030100056 A ARP030100056 A AR P030100056A AR 038178 A1 AR038178 A1 AR 038178A1
Authority
AR
Argentina
Prior art keywords
group
alkyl
atom
amino
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
ARP030100056A
Other languages
Spanish (es)
Inventor
Leo Thomas
Michael Mark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2002100633 external-priority patent/DE10200633A1/en
Priority claimed from DE10256184A external-priority patent/DE10256184A1/en
Application filed by Boehringer Ingelheim Pharma GmbH Co KG filed Critical Boehringer Ingelheim Pharma GmbH Co KG
Publication of AR038178A1 publication Critical patent/AR038178A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Utilización de fibratos para reducir la toxicidad hepática de inhibidores PTM, proteína de transferencia de triglicéridos microsomal, así como composiciones farmacéuticas que contienen un inhibidor de PTM y un fibrato. Reivindicación 3: Utilización según la reivindicación 1 ó 2, siendo el inhibidor de PTM un compuesto de la fórmula general (1), en la que: X1 significa el grupo CR1, X2 significa el grupo CR2, X3 significa el grupo CR3 y X4 significa el grupo CR4, o uno o dos de los grupos X1 a X4 significan en cada caso un átomo de N y los restantes grupos X1 a X4 significan tres o dos de los grupos CR1 a CR4, significando R1, R2, R3 y R4 en cada caso un átomo de H o significando uno o dos de los grupos R1 a R4, independientemente uno de otro, en cada caso un átomo de F, Cl, o Br, un grupo alquilo C1-3, un grupo trifluorometilo, hidroxi, alcoxi C1-3, trifluorometoxi, amino, alquil C1-3-amino o di-(alquil C1-3)-amino y significando los restantes grupos R1 a R4 en cada caso un átomo de H, pudiendo adoptar R4, adicionalmente, junto con R5 el significado de un puente -(CH2)n, en el que n representa el número 1, 2 ó 3 y Aa significa un enlace, un átomo de O ó S, un grupo -NH-, -N(alquilo C1-3)-, sulfinilo, sulfonilo o carbonilo, uno de los grupos -CH2-, -(CH2)2-, -CH=CH-, -CsC-, -OCH2-, -CH2O, -NH-CH2-, -CH2-NH-,-NH-CO-, -CO-NH-, -NH-SO2- o -SO2-NH-, en los que un átomo de H unido a un átomo de C y/o un átomo de H unido a un átomo de N puede estar en cada caso reemplazado por un grupo alquilo C1-3, y en donde un heteroátomo del grupo Aa no está enlazado con un átomo de N de un grupo heteroarilo de 5 miembros del grupo Ra, Ra significa un grupo fenilo, 1-naftilo o 2-naftilo, un grupo heteroarilo de 5 miembros unido a través de un átomo de C o N que contiene un grupo imino, eventualmente sustituido con un grupo alquilo C1-4, o alquil C1-4-carbonilo, un átomo de O ó S, un grupo imino, eventualmente sustituido con un grupo alquilo C1-4 o un átomo de O ó S y , adicionalmente, un átomo de N, o un grupo imino, eventualmente sustituido con un grupo alquilo C1-4 y dos átomos de N, o un átomo de O ó S y dos átomos de N, un grupo heteroarilo de 6 miembros que contiene uno o dos átomos de N, pudiendo estar condensado un anillo de fenilo a los grupos heteroarilo de 5 o 6 miembros precedentemente mencionados a través de dos átomos de C contiguos y pudiendo estar unidos los grupos heteroarilo bicíclicos, así formados, a través de la parte heteroatómica o carbocíclica y pudiendo estar monosustituido los grupos fenilo y naftilo, así como los radicales heteroarilo monocíclicos y bicíclicos precedentemente mencionados, en el esqueleto de carbonos, con un átomo de F, Cl, o Br, con un grupo alquilo C1-4 ,con un grupo cicloalquilo C3-7, trifluorometilo, fenilo, hidroxi, alcoxi C1-3, trifluorometoxi, amino, alquilo C1-3-amino, di-(alquil C1-3)-amino, acetilamino, N-(alquil C1-3)-acetil-amino, propionilamino, N-(alquil C1-3)-propionilamino, acetilo, propionilo, alcoxi C1-3-carbonilo, aminocarbonilo, alquil C1-3-amino-carbonilo, di-(alquil C1-3)-amino-carbonilo o ciano o con excepción de radicales heteroarilo de 5 miembros que contienen más de dos heteroátomos, pudiendo estar también di-sustituidos con los sustituyentes precedentemente mencionados, pudiendo ser los sustituyentes iguales o diferentes, un grupo cicloalquilo C3-7, pudiendo estar reemplazado en cada caso el grupo metileno en posición 4 de un radical cicloalquilo de 6 o 7 miembros con un átomo de O ó S, con un grupo sulfinilo o sulfonilo o con un grupo imino, eventualmente sustituido con un grupo alquilo C1-5, fenilo, alquil C1-4-carbonilo, alcoxi C1-4-carbonilo, alquil C1-3-aminocarbonilo o di-(alquil C1-3)-amino-carbonilo, un grupo cicloalquilenimino de 4 a 7 miembros, en el que la parte de cicloalquileno puede estar condensada con un anillo de fenilo o uno o dos átomos de H pueden estar reemplazados en cada caso con un grupo alquilo C1-3 y/o en cada caso el grupo metileno en posición 4 de un grupo cicloalquilenimino de 6 o 7 miembros puede estar sustituido con un grupo hidroxicarbonilo, alcoxi C1-3-carbonilo, amino, alquil C1-3-amino, di-(alquil C1-3)-amino, aminocarbonilo, alquil C1-3-amino-carbonilo, di-(alquil C1-3)-aminocarbonilo o fenil-alquil C1-3-amino, o con un átomo de O ó S, con un grupo sulfinilo o sulfonilo o con un grupo imino eventualmente sustituido con un grupo alquilo C1-5, fenilo, alquil C1-4-carbonilo, alcoxi C1-4-carbonilo, alquil C1-3-aminocarbonilo o di-(alquil C1-3)-aminocarbonilo, o en un grupo cicloalquilenimino de 5, 6 o 7 miembros, un grupo -CH2 enlazado con el átomo de N de imino puede estar reemplazado por un grupo carbonilo o un grupo -(CH2)2- enlazado con el átomo de N de imino puede estar reemplazado por un grupo -CO-NR8, o un grupo -(CH2)3 enlazado con el átomo de N de imino puede estar reemplazado por un grupo -CO-NR8-CO, representando R8 un átomo de H o un grupo alquilo C1-3, R5 significa un átomo de H o un grupo alquilo C1-5, Het significa un grupo heteroarileno de 5 miembros unido a través de dos átomos de C o, si Het significa un grupo pirrol de doble enlace, unido también a través de un átomo de C y el átomo de N de imino, estando enlazado este último con el grupo carbonilo contiguo en la fórmula (1), el cual contiene un grupo imino sustituido con el grupo R9, un átomo de O ó S o un grupo imino sustituido con el grupo R9 o un átomo de O ó S y, adicionalmente, un átomo de N, significando R9 un átomo de H, un grupo alquilo C1-5, un grupo alquilo C2-3 sustituido en posición terminal con un grupo amino, alquil C1-3-amino, di-(alquil C1-3)-amino o alcoxi C1-5-carbonil-amino, un grupo carboxi-alquilo C1-3, alcoxi C1-3-carbonil-alquilo C1-3, fenilo, fenil-alquilo C1-3, alquil C1-5-carbonilo o fenilcarbonilo, o R9, junto con R6, representa un puente -(CH2)p, en el que p significa el número 2 ó 3, o un grupo imino eventualmente sustituido con un grupo alquilo C1-3 y dos átomos de N, o un átomo de O ó S y dos átomos de N, o significa un grupo heteroarileno de 6 miembros que contiene uno o dos átomos de N, estando los radicales heteroarileno precedentemente mencionados monosustituidos en el esqueleto de carbonos con un átomo de F, Cl, o Br, con un grupo alquilo C1-5, con un grupo cicloalquilo C3-7, trifluorometilo, hidroxi, alcoxi C1-3, trifluorometoxi, amino, alquil C1-3-amino, di-(alquil C1-3)-amino, acetilamino, N-(alquil C1-3)-acetilamino, propionilamino, N-(alquil C1-3)-propionilamino, acetilo, propionilo, benzoilo, alcoxi C1-3-carbonilo, aminocarbonilo, alquil C1-3amino-carbonilo, di-(alquil C1-3)-amino-carbonilo o ciano o, con excepción de radicales heteroarilo monocíclicos de 5 miembros que contienen más de un heteroátomo, pudiendo estar también disustituido con los sustituyentes precedentemente mencionados, pudiendo ser los sustituyentes iguales o diferentes, R6 significa un átomo de H o un grupo alquilo C1-6, R7 significa un grupo alquilo C1-9, un grupo alquenilo C3-9 o alquinilo C3-9 de cadena lineal o ramificada e insaturado una vez, dos veces o tres veces, estando aislados los enlaces múltiples del enlace N-C, un grupo alquilo C2-6 de cadena lineal que está sustituido en posición terminal con un grupo amino, alquil C1-3-amino o di-(alquil C1-3)-amino, un grupo alquilo C1-6 sustituido con un radical cicloalquilo C3-7, pudiendo estar reemplazado un átomo de H en posición 3 del radical ciclopentilo y en posición 4 de un radical cicloalquilo de 6 o 7 miembros, en cada caso con un grupo hidroxi, hidroxi-alquilo C1-3, alcoxi C1-5, alcoxi C1-5-alquilo C1-3, fenil-alcoxi C1-3-alquilo C1-3, amino, alquil C1-5-amino, di-(alquil C1-5)-amino, fenil-alquil C1-3-amino, alquil C1-5-carbonilamino, benzoil-amino, amino-alquilo C1-3, alquil C1-3-amino-alquilo C1-3, di-(alquil C1-3)-amino-alquilo C1-3, fenil-alquil C1-3-amino-alquilo C1-3, alquil C1-3-carbonilamino-alquilo C1-3, benzoilamino C1-3, fenilamino-carbonilo, fenil-alquil C1-3-amino-carbonilo, carboxi o alcoxi C1-3-carbonilo o pudiendo estar reemplazado en cada caso el grupo metileno en posición 4 de un radical cicloalquilo de 6 o 7 miembros con un átomo de, O ó S o con un grupo imino eventualmente sustituido con un grupo alquilo C1-6, fenilo, alquil C1-6-carbonilo, benzoílo, fenil-(alquil C1-3)-carbonilo, alquil C1-6-aminocarbonilo, di-(alquil C1-5)-aminocarbonilo, fenilamino-carbonilo, N-(alquil C1-3)-fenilcarbonilo, fenil-alquil C1-3-aminocarbonilo o N-(alquil C1-3)-fenil-alquilo C1-3-amino-carbonilo o pudiendo estar condensados en un radical cicloalquilo de 5 o 6 miembros uno o dos enlaces simples separados por al menos un enlace entre sí y separados de la posición 1, en cada caso con un radical fenilo, en donde en un sistema de anillo bicíclico o tricíclico así formado, el átomo de H unido al átomo de C saturado en la posición 1 puede estar reemplazado por un grupo alquil C1-5-amino-carbonilo, di-(alquil C1-5)-amino-carbonilo, fenil-alquil C1-3-amino-carbonilo o alcoxi C1-5-carbonilo, en los que grupos metilo terminales pueden estar fluorados en cada caso total o parcialmente, significa un grupo alquilo C1-6 eventualmente sustituido con un grupo cicloalquilo C3-7, que está sustituido con un grupo carboxi o alcoxi C1-3-carbonilo, con un grupo fenilo, 1-naftilo o 2-naftilo, con un grupo heteroarilo de 5 miembros unido a través de un átomo de C o N, que contiene un grupo imino eventualmente sustituido con un grupo alquilo C1-3, trifluorometilo, fenilo, fenil-alquilo C1-3, alquil C1-3-carbonilo, fenilcarbonilo o fenil-alquil C1-3-carbonilo, un átomo de O ó S, un grupo imino eventualmente sustituido con un grupo alquilo C1-3 o un átomo de O ó S y, adicionalmente, un átomo de N, o grupo imino eventualmente sustituido con un grupo alquilo C1-3 y dos átomos de N o un átomo de O ó S y dos átomos de N, con un grupo heteroarilo de 6 miembros que contiene uno dos átomos de N, pudiendo estar condensado un anillo de fenilo a los grupos heteroarilo de 5 o 6 miembros precedentemente mencionados a través Use of fibrates to reduce liver toxicity of PTM inhibitors, microsomal triglyceride transfer protein, as well as pharmaceutical compositions containing a PTM inhibitor and a fibrate. Claim 3: Use according to claim 1 or 2, the PTM inhibitor being a compound of the general formula (1), wherein: X1 means the group CR1, X2 means the group CR2, X3 means the group CR3 and X4 means the group CR4, or one or two of the groups X1 to X4 mean in each case an atom of N and the remaining groups X1 to X4 mean three or two of the groups CR1 to CR4, meaning R1, R2, R3 and R4 in each case an atom of H or meaning one or two of the groups R1 to R4, independently of each other, in each case an atom of F, Cl, or Br, a C1-3 alkyl group, a trifluoromethyl, hydroxy, C1 alkoxy group -3, trifluoromethoxy, amino, C1-3-alkyl or di- (C1-3 alkyl) -amino and the remaining groups R1 to R4 meaning in each case an atom of H, being able to adopt R4, in addition, together with R5 the meaning of a bridge - (CH2) n, where n represents the number 1, 2 or 3 and Aa means a bond, an O or S atom, a group -NH-, -N (C1-3 alkyl ) -, sulfinyl, sulfonyl or carbonyl, one of the groups -CH2-, - (CH2) 2-, -CH = CH-, -CsC-, -OCH2-, -CH2O, -NH-CH2-, -CH2- NH -, - NH-CO-, -CO-NH-, -NH-SO2- or -SO2-NH-, in which an H atom attached to a C atom and / or an H atom attached to a N atom may in each case be replaced by a C1-3 alkyl group, and where a heteroatom of group Aa is not linked to an N atom of a 5-membered heteroaryl group of group Ra, Ra means a phenyl group, 1-naphthyl or 2-naphthyl, a 5-membered heteroaryl group linked through a C or N atom containing an imino group, optionally substituted with a C1-4 alkyl group, or C1-4 alkylcarbonyl group, an atom of O or S, an imino group, optionally substituted with a C1-4 alkyl group or an O or S atom and, additionally, an N atom, or an imino group, optionally substituted with a C1-4 alkyl group and two N atoms, or an O or S atom and two N atoms, a 6-membered heteroaryl group that contains in one or two N atoms, a phenyl ring may be condensed to the aforementioned 5 or 6-membered heteroaryl groups through two contiguous C atoms and the bicyclic heteroaryl groups thus formed can be attached through the heteroatomic or carbocyclic part and the phenyl and naphthyl groups may be monosubstituted, as well as the above-mentioned monocyclic and bicyclic heteroaryl radicals, in the carbon skeleton, with an atom of F, Cl, or Br, with a C1-4 alkyl group, with a C3-7 cycloalkyl, trifluoromethyl, phenyl, hydroxy, C1-3 alkoxy, trifluoromethoxy, amino, C1-3-alkyl, di- (C1-3 alkyl) -amino, acetylamino, N- (C1-3 alkyl) group ) -acetyl-amino, propionylamino, N- (C1-3 alkyl) -propionylamino, acetyl, propionyl, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkyl-carbonyl alkyl, di- (C1-3 alkyl) - aminocarbonyl or cyano or with the exception of 5-membered heteroaryl radicals containing more than do s heteroatoms, which may also be di-substituted with the above-mentioned substituents, the substituents being the same or different, a C3-7 cycloalkyl group, the methylene group in position 4 of a cycloalkyl radical of 6 or 7 may be replaced in each case. members with an O or S atom, with a sulfinyl or sulfonyl group or with an imino group, optionally substituted with a C1-5 alkyl group, phenyl, C1-4 alkylcarbonyl, C1-4 alkoxycarbonyl, C1- alkyl 3-aminocarbonyl or di- (C1-3 alkyl) -aminocarbonyl, a 4- to 7-membered cycloalkyleneimino group, in which the cycloalkylene part may be condensed with a phenyl ring or one or two H atoms. replaced in each case with a C1-3 alkyl group and / or in each case the methylene group in position 4 of a 6 or 7 membered cycloalkyleneimino group may be substituted with a hydroxycarbonyl, C1-3 alkoxycarbonyl, amino, alkyl group C1-3-amino, di- (C1-3 alkyl) -ami no, aminocarbonyl, C1-3-alkylcarbonyl, di- (C1-3alkyl) -aminocarbonyl or phenyl-C1-3-amino alkyl, or with an O or S atom, with a sulfinyl or sulfonyl group or with an imino group optionally substituted with a C1-5 alkyl, phenyl, C1-4 alkylcarbonyl, C1-4 alkoxycarbonyl, C1-3 alkylcarbonyl or di- (C1-3 alkyl) aminocarbonyl group, or in a 5, 6 or 7 membered cycloalkyleneimino group, a -CH2 group linked to the imino N atom can be replaced by a carbonyl group or a group ((CH2) 2- linked to the imino N atom can be replaced by a group -CO-NR8, or a group - (CH2) 3 linked to the imino N atom can be replaced by a group -CO-NR8-CO, R8 representing an atom of H or a C1-3 alkyl group, R5 means an H atom or a C1-5 alkyl group, Het means a 5-membered heteroarylene group linked through two C atoms or, if Het means a double bond pyrrole group, also linked through a C atom and imino N atom, the latter being linked to the contiguous carbonyl group in formula (1), which contains an imino group substituted with the R9 group, an O or S atom or a substituted imino group with the R9 group or an O or S atom and, additionally, an N atom, R9 meaning an H atom, a C1-5 alkyl group, a C2-3 alkyl group substituted in the terminal position with an amino, alkyl group C1-3-amino, di- (C1-3 alkyl) -amino or C1-5 alkoxycarbonyl amino, a carboxy-C1-3 alkyl, C1-3 alkoxycarbonyl C1-3 alkyl, phenyl, phenyl - C1-3 alkyl, C1-5 alkylcarbonyl or phenylcarbonyl, or R9, together with R6, represents a bridge - (CH2) p, in which p means the number 2 or 3, or an imino group optionally substituted with a C1-3 alkyl group and two N atoms, or an O or S atom and two N atoms, or means a 6-membered heteroarylene group containing one or two N atoms, the heteroarylene radicals being previously me monosubstituted in the carbon skeleton with an atom of F, Cl, or Br, with a C1-5 alkyl group, with a C3-7 cycloalkyl group, trifluoromethyl, hydroxy, C1-3 alkoxy, trifluoromethoxy, amino, C1- alkyl 3-amino, di- (C1-3 alkyl) -amino, acetylamino, N- (C1-3 alkyl) -acetylamino, propionylamino, N- (C1-3 alkyl) -propionylamino, acetyl, propionyl, benzoyl, C1- alkoxy 3-carbonyl, aminocarbonyl, C1-3alkylcarbonyl, di- (C1-3alkyl) -aminocarbonyl or cyano or, with the exception of 5-membered monocyclic heteroaryl radicals containing more than one heteroatom, may also be disubstituted with the above-mentioned substituents, the substituents being the same or different, R6 means an H atom or a C1-6 alkyl group, R7 means a C1-9 alkyl group, a C3-9 alkenyl or C3-9 straight chain alkynyl group or branched and unsaturated once, twice or three times, multiple links being isolated from the NC link, a group C2-6 straight chain alkyl which is substituted in the terminal position with an amino group, C1-3 alkyl or amino- or di- (C1-3 alkyl) -amino, a C1-6 alkyl group substituted with a C3-7 cycloalkyl radical , an H atom can be replaced in position 3 of the cyclopentyl radical and in position 4 of a 6 or 7 membered cycloalkyl radical, in each case with a hydroxy, hydroxy-C1-3 alkyl, C1-5 alkoxy, C1 alkoxy group -5-C1-3 alkyl, phenyl-C1-3alkoxy-C1-3 alkyl, amino, C1-5-alkyl, di- (C1-5 alkyl) -amino, phenyl-C1-3-alkyl, alkyl C1-5-carbonylamino, benzoyl-amino, amino-C1-3alkyl, C1-3alkyl-C1-3alkyl, di- (C1-3alkyl) -amino-C1-3alkyl, phenyl-C1-alkyl 3-amino C1-3 alkyl, C1-3 alkylcarbonylamino C1-3 alkyl, benzoylamino C1-3, phenylaminocarbonyl, phenyl C1-3 alkyl aminocarbonyl, carboxy or C1-3 alkoxycarbonyl or the methylene group in position 4 of a 6 or 7-membered cycloalkyl radical may be replaced in each case with an att mo of, O or S or with an imino group optionally substituted with a C1-6 alkyl group, phenyl, C1-6 alkylcarbonyl, benzoyl, phenyl- (C1-3 alkyl) -carbonyl, C1-6 alkylcarbonyl alkyl, di- (C1-5 alkyl) -aminocarbonyl, phenylaminocarbonyl, N- (C1-3 alkyl) -phenylcarbonyl, phenyl-C1-3-alkylcarbonyl or N- (C1-3 alkyl) -phenyl-C1-3 alkyl -amino-carbonyl or one or two single bonds separated by at least one bond from each other and separated from the 1 position, in each case with a phenyl radical, where in a system may be condensed in a 5 or 6 membered cycloalkyl radical with a bicyclic or tricyclic ring thus formed, the H atom attached to the saturated C atom in position 1 may be replaced by a C1-5-amino-carbonyl alkyl, di- (C1-5 alkyl) -amino-carbonyl group, phenyl-C1-3-alkyl-carbonyl or C1-5-alkoxycarbonyl, in which terminal methyl groups can be fluorinated in each case wholly or partially, means a C1-6 alkyl group eventually entity substituted with a C3-7 cycloalkyl group, which is substituted with a carboxy or C1-3-alkoxycarbonyl group, with a phenyl, 1-naphthyl or 2-naphthyl group, with a 5-membered heteroaryl group linked through a C or N atom, which contains an imino group optionally substituted with a C1-3 alkyl, trifluoromethyl, phenyl, phenyl-C1-3 alkyl, C1-3 alkylcarbonyl, phenylcarbonyl or phenyl-C1-3alkyl alkyl group, an O or S atom, an imino group optionally substituted with a C1-3 alkyl group or an O or S atom and, additionally, an N atom, or imino group optionally substituted with a C1-3 alkyl group and two atoms of N or an O or S atom and two N atoms, with a 6-membered heteroaryl group containing one two N atoms, a phenyl ring may be condensed to the 5 or 6-membered heteroaryl groups mentioned above through

ARP030100056A 2002-01-10 2003-01-10 COMBINATION OF PTM INHIBITORS OR INHIBITORS OF THE APOB SECRETION WITH FIBRATES FOR USE AS MEDICATIONS Withdrawn AR038178A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2002100633 DE10200633A1 (en) 2002-01-10 2002-01-10 Reducing hepatotoxicity of microsomal triglyceride transfer protein inhibitors, used e.g. in treatment of hyperlipemia, atherosclerosis or diabetes, by co-administration with fibrate
DE10256184A DE10256184A1 (en) 2002-12-02 2002-12-02 Reducing hepatotoxicity of microsomal triglyceride transfer protein inhibitors, used e.g. in treatment of hyperlipemia, atherosclerosis or diabetes, by co-administration with fibrate

Publications (1)

Publication Number Publication Date
AR038178A1 true AR038178A1 (en) 2005-01-05

Family

ID=26010911

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100056A Withdrawn AR038178A1 (en) 2002-01-10 2003-01-10 COMBINATION OF PTM INHIBITORS OR INHIBITORS OF THE APOB SECRETION WITH FIBRATES FOR USE AS MEDICATIONS

Country Status (9)

Country Link
EP (1) EP1465613A2 (en)
JP (1) JP2005525309A (en)
AR (1) AR038178A1 (en)
AU (1) AU2003205570A1 (en)
CA (1) CA2471566A1 (en)
PE (1) PE20030924A1 (en)
TW (1) TW200402292A (en)
UY (1) UY27610A1 (en)
WO (1) WO2003057205A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
MXPA05006744A (en) * 2002-12-20 2005-09-08 Pfizer Prod Inc Microsomal triglyceride transfer protein inhibitors.
JP2007008816A (en) * 2003-10-15 2007-01-18 Ube Ind Ltd New isoquinoline derivative
US7648998B2 (en) 2003-12-22 2010-01-19 K.U. Leuven Research & Development Imidazo 4,5-c pyridine compounds and methods of antiviral treatment
AU2005319167B2 (en) 2004-12-21 2011-09-29 Gilead Sciences, Inc. Imidazo[4,5-C]pyridine compound and method of antiviral treatment
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
KR20080031038A (en) * 2005-07-29 2008-04-07 4에스체 악티엔게젤샤프트 NOVEL HETEROCYCLIC NF-kappa;B INHIBITORS
WO2008005519A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc. Novel pyridazine compound and use thereof
JP5642922B2 (en) * 2007-04-24 2014-12-17 サントリーホールディングス株式会社 Evaluation method of liver injury using multiple liver injury markers as indicators
CL2008001933A1 (en) 2007-06-29 2009-09-25 Millennium Pharm Inc Pyrimidine derived compounds, raph kinase inhibitors; intermediate compounds; preparation procedure; pharmaceutical composition; and its use to treat proliferative, cardiac, neurodegenerative, inflammatory, bone, immunological, viral disease, among others.
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
EP2438059A1 (en) 2009-06-05 2012-04-11 Link Medicine Corporation Aminopyrrolidinone derivatives and uses thereof
JOP20200001A1 (en) 2017-07-11 2022-10-30 Vertex Pharma Carboxamides as modulators of sodium channels
SI3762368T1 (en) 2018-03-08 2022-06-30 Incyte Corporation Aminopyrazine diol compounds as pi3k-y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
CA2325358C (en) * 1999-11-10 2005-08-02 Pfizer Products Inc. 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
DE10033337A1 (en) * 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarboxamides, their preparation and their use as medicaments
DE10132686A1 (en) * 2001-07-05 2003-01-16 Boehringer Ingelheim Pharma Heteroarylcarboxamides, their preparation and their use as medicines

Also Published As

Publication number Publication date
WO2003057205A2 (en) 2003-07-17
UY27610A1 (en) 2003-08-29
PE20030924A1 (en) 2003-12-17
AU2003205570A1 (en) 2003-07-24
AU2003205570A8 (en) 2003-07-24
WO2003057205A3 (en) 2004-04-01
JP2005525309A (en) 2005-08-25
CA2471566A1 (en) 2003-07-17
EP1465613A2 (en) 2004-10-13
TW200402292A (en) 2004-02-16

Similar Documents

Publication Publication Date Title
AR038178A1 (en) COMBINATION OF PTM INHIBITORS OR INHIBITORS OF THE APOB SECRETION WITH FIBRATES FOR USE AS MEDICATIONS
AR033620A1 (en) ALFA-AMINO ACIDS SULFONYL COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
AR094601A2 (en) HEXAHYDROCICLOPENTA DERIVATIVES [C] PIRROL AS ACTIVATORS OF CENTRAL HISTAMINERGIC SYSTEMS, THEIR USE AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
UY27619A1 (en) ESTERS HYDROXAMATE OF ACID N- (SUBSTITUTED 4-PHENYL) - ANTRANÍLICO
ECSP056065A (en) Pharmaceutical compositions for hepatitis C virus protease inhibitors
ME00561B (en) Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
CY1126067T1 (en) FUSIONED PYROLINES THAT ACT AS UBIQUITIN-SPECIFIC PROTEASE 30 (USP30) INHIBITORS
AR061238A1 (en) HEPATITIS C PROTEASE INHIBITORS MACROCICLIC OXYLMYL COMPOUNDS
PA8792501A1 (en) NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.
AR048401A1 (en) HCV SERINE-PROTEASA NS3 INHIBITORS
WO2008065500A3 (en) Heteroaryl amides as type i glycine transport inhibitors
UY33617A (en) INHIBITORS OF HCV SERINE PROTEASES DERIVED FROM MACROCYCLINE PROLINES
AR056347A1 (en) USE OF PTERIDINE COMPOUNDS TO MANUFACTURE PHARMACEUTICAL MEDICINES AND COMPOSITIONS
CO6351741A2 (en) CRYSTAL FORMS OF A DERIVATIVE OF 2-TIAZOLIL-4-QUINOLINIL-OXI, A POWERFUL HCV INHIBITOR
UY27618A1 (en) ESTERS HYDROXAMATE ACID N- (4-PHENYL-SUBSTITUTED) -ANTRANILIC
CO5611113A2 (en) TRIPEPTIDES THAT HAVE A HYDROXIPROLIN ETER OF A REPLACED QUINOLINE FOR THE INHIBITION OF NS3 (HEPATITIS C)
AR067674A1 (en) USEFUL PIRAZOL DERIVATIVES FOR TREATMENT WITH A CCR2 RECEIVER ANTAGONIST
ECSP10010254A (en) COMPOUNDS CONTAINING QUINOXALINE AS INHIBITORS OF THE HEPATITIS C VIRUS
CY1117449T1 (en) N-ACYL FINISHED AMIN AND AMINO ACID PRODUCERS, METHODS FOR PRODUCING THESE, A PHARMACEUTICAL COMPOSITION AND USE OF THESE
PE20120516A1 (en) MAP KINASE INHIBITOR P38
AR062797A1 (en) PIPERIDINE DERIVATIVES AS RENINE INHIBITORS, PHARMACEUTICAL COMPOSITIONS.
CO6351740A2 (en) SYNERGIC COMBINATIONS OF A HCV MACROCICLIC INHIBITOR AND A NUCLEOSIDE
CL2011002643A1 (en) Pharmaceutical composition comprising r7227, ritonavir and a pharmaceutically acceptable excipient; kit for the treatment of hepatitis c virus.
EA200801619A1 (en) METHOD OF IMPROVING PHARMACOKINETICS INHIBITORS INHIBITORS HIV (OPTIONS), SET AND PHARMACEUTICAL COMPOSITION (OPTIONS)
UY28897A1 (en) ACID 2 - ((2- (2-METHYLAMINOPIRIMIDIN-4-IL) -1H-INDOL-5-CARBONYL) AMINO) -3- (PHENYLPIRIDIN-2-ILAMINO) SUBSTANTIALLY PURE PROPIONIC AS INHIBITOR OF THE IKB KINASE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal